跳至主導覽
跳至搜尋
跳過主要內容
臺北醫學大學 首頁
說明與常見問題
English
中文
首頁
專家檔案
研究單位
專案
研究成果
資料集
活動
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
陳 奕安
主治醫師
,
臺北市立萬芳醫院
成員
,
臺北神經醫學中心
電子郵件
105131
w.tmu.edu
tw
h-index
68
引文
5
h-指數
按照存儲在普爾(Pure)的出版物數量及斯高帕斯(Scopus)引文計算。
2012
2024
每年研究成果
概覽
指紋
網路
研究成果
(8)
資料集
(9)
類似的個人檔案
(7)
指紋
查看啟用 Yi-An Chen 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Biochemistry, Genetics and Molecular Biology
Oxytocin
25%
Omega 3 Fatty Acid
25%
Genetic Divergence
25%
Randomized Controlled Trial
25%
LNCaP
25%
Polyunsaturated Fatty Acid
25%
Prolactin
25%
Olanzapine
25%
Folic Acid Blood Level
25%
Cancer Cell
25%
Dihydrofolate Reductase
25%
Methylenetetrahydrofolate Reductase
25%
Autophagy
25%
Radiosensitivity
25%
Arsenite
25%
Arsenic Trioxide
25%
Cluster Analysis
25%
Light Chain
25%
Neurofilament
25%
Folic Acid
14%
Genetics
11%
LY294002
8%
In Vivo Study
8%
Akt/mTOR Signaling
8%
Homeostasis
8%
Prevalence
8%
Cell Death
8%
Cytotoxicity
8%
Tumor Progression
8%
Mental Health
8%
Cross Sectional Study
7%
Carbon Metabolism
7%
Insulin Level
5%
Awareness
5%
Insulin Resistance
5%
Pharmacology, Toxicology and Pharmaceutical Science
Metabolic Disorder
50%
Metabolic Syndrome X
35%
Olanzapine
28%
Antipsychotic
25%
Omega-3 Fatty Acid
25%
Randomized Controlled Trial
25%
Prostate Cancer
25%
Arsenite
25%
Hyperprolactinemia
25%
Adiponectin
25%
Androgen
25%
Prolactin
25%
Typical Antipsychotic
21%
Oxytocin
18%
Disease
14%
Pathophysiology
12%
Ionizing Radiation
10%
Negative Syndrome
7%
Positive Syndrome
7%
Monotherapy
7%
Prevalence
6%
Cognitive Defect
6%
2 Morpholino 8 Phenylchromone
5%
Tumor Growth
5%
Antidepressant
5%
Cytotoxicity
5%
3 Methyladenine
5%
Cross-Sectional Study
5%
Malignant Neoplasm
5%
Insulin Resistance
5%
Combination Therapy
5%
Neuroscience
Dementia Praecox
100%
Olanzapine
29%
Cognitive Disorders
28%
Adiponectin
25%
Meta-Analysis
25%
Prolactin
25%
Randomized Controlled Trial
25%
Omega 3 Fatty Acid
25%
Major Depressive Disorder
25%
Typical Antipsychotic
25%
Neurofilament Light Chain
25%
Antipsychotic
12%
Oxytocin
9%
Positive Syndrome
7%
Negative Syndrome
7%
Neurodegenerative Disorder
5%
Treatment of Schizophrenia
5%
Antidepressant
5%